CClinicalTrials.gg
RecruitingNCT07500714Updated Mar 30, 2026

Integrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine

An interventional study of Internet Cognitive-Behavioral Therapy and Sham treatment in Depression - Major Depressive Disorder, sponsored by National Science and Technology Council, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by National Science and Technology Council, Taiwan · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2025, registered Mar 2026).
  • Started Jun 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This project aims to integrate digital phenotyping and AI-driven iCBT into a comprehensive platform for MDD diagnosis and treatment in Taiwan. The study will explore dynamic, real-time behavioral and physiological markers to refine diagnostic classifications and optimize personalized therapeutic strategies.

02

Conditions studied

  • Depression - Major Depressive Disorder
03

In context

Lead sponsor

National Science and Technology Council, Taiwan is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • (1) Aged 18-75 years
  • Diagnosis of major depressive disorder disorder (Based on Diagnostic Statistical Manual 5)
  • 21-item Hamilton Depression Scale (HAMD21)>17
  • No changes in current psychiatric treatment for depression (e.g., no treatment, antidepressant medication, psychotherapy, or non-invasive brain stimulation) within the past four weeks, and
  • Full competency to understand the study details and provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Scores of 5 ( Markedly ill), 6,(Severely ill), and 7 (Among the most extremely ill) according to the Clinical Global Impression Scale-Severity (CGI-S)
  • Psychotic disorders, bipolar affective disorder, a substance use disorders in the past 6 months, active suicidal or homicidal ideation (per assessment or HAMD>3)
  • Unstable or active medical illness.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    GPT-powered iCBT

    Behavioral: Internet Cognitive-Behavioral Therapy

  • Sham comparator
    Sham

    Behavioral: Sham treatment

Interventions

  • BehavioralInternet Cognitive-Behavioral Therapy

    GPT-powered iCBT the participants will receive 8 sessions (30 minutes per session)

    Also known as: iCBT

  • BehavioralSham treatment

    Sham (relaxation/supportive interaction) treatment at Day 2, 5, 9, 12, 16, 19, 23, 27.

06

What researchers measure

Primary outcomes

  1. Depression Severity

    Depression severity is measured by the 21-item Hamilton Rating Scale for Depression (HAM-D). A higher score indicates greater severity, a score of ≥18 indicates moderate to severe depression.

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

  2. Depression Severity

    Depression severity is measured by the 9-item Patient Health Questionnaire (PHQ-9). A score of ≥10 is the most common threshold used to identify individuals likely to have major depressive disorder.

    Time frame: Weeks 0, 1, 2, 4, 8,12, 16, 20, 24

  3. Stress Level

    Stress level is measured by the Life Events Perceived Stress (LEPS). A total score of ≥27 is widely recognized as the cut-off for high perceived stress.

    Time frame: Weeks 0, 1, 2, 4, 8,12, 16, 20, 24

  4. Quality of Life Assessment

    Quality of Life Assessment is measured by the EuroQol questionnaire (EQ-5D). The Index Score (usually 0 to 1), where 1.0 is full health, index scores below 0.6 are often characterized as representing low quality of life

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

Secondary outcomes

  1. Psychological well-being

    Psychological well-being is measured by the Brief Live Experience Questionnaire (BLEQ12). Score Range: 0-36; higher scores indicate greater general psychological well-being.

    Time frame: Weeks 0, 4

  2. Resilience Scale

    Resilience is measured by the Resilience Scale for Adults (RSA). The scale uses a 7-point semantic differential scale (e.g., ranging from "Difficult to accomplish" to "Possible to accomplish"), with a total score range of: 33 to 231.

    Time frame: Weeks 0, 4

  3. Potential traumatic experiences

    Resilience is measured by the Adverse Childhood Experiences-International Questionnaire. ACE Score (0-13): One point is given for each category of trauma experienced. The "Cut-off": A score of ≥4 is the widely recognized threshold where the risk of chronic disease, depression, and social problems increases significantly.

    Time frame: Weeks 0, 4

  4. Nutrition Assessment

    Nutrition Assessment is measured by the Taiwanese version of the Mini Nutrition Assessment (MNA). The MNA Long Form consists of 18 items with a maximum score of 30 points, where a score of 24 to 30 points indicates normal nutritional status, 17 to 23.5 points indicates a risk of malnutrition, and less than 17 points signifies that the individual is malnourished.

    Time frame: Weeks 0, 4

  5. Peripheral Neuropathy Symptom Assessment

    Peripheral Neuropathy Symptom is measured by the self-reported Neurotoxicity Rating Scale (NTRS)

    Time frame: Weeks 0, 4

  6. Physical Activity Level

    Continuous monitoring of daily physical activity via the Garmin Vívoactive 5 wearable device. Unit of Measure: number of steps per day. \<5,000 steps/day is often defined as "sedentary," while \>7,500 steps/day is "physically active"

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

  7. Heart Rate Variability (HRV)

    Continuous monitoring of the variation in time between consecutive heartbeats measured during rest using the Garmin Vívoactive 5. Unit of Measure: Root mean square of successive differences (RMSSD) in milliseconds (ms). Absolute Values (RMSSD): For healthy adults (ages 38-42), a normal range is typically 19-48 ms. Scores significantly below this (e.g., \<20 ms) are often used as a cut-off for high physiological stress or poor recovery.

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

  8. Sleep Patterns (Sleep Score)

    Continuous monitoring is measured using the Garmin Vívoactive 5. Garmin's internal "Sleep Score" (0-100) uses 60 as the threshold for "Poor" sleep. A higher score shows better results.

    Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, 24

07

Study locations

1 of 1 sites recruiting
  • Mind Body Interface Research Center (MBI Lab & Care)
    Taichung, Taichung 404, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07500714
Lead sponsor
National Science and Technology Council, Taiwan
Responsible party
Kuan-Pin (Professor, National Science and Technology Council, Taiwan) — Principal investigator
First posted
Mar 30, 2026
Start date
Jun 1, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Kuan-Pin Su, MD, PhD.
Contact
cobol@cmu.edu.tw
04-22361230

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion